PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 9, 2024Transfusion5 citations

How do I implement pathogen reduced Cryoprecipitated fibrinogen complex in a tertiary Hospital's blood Bank

View Full Paper
JAJennifer AidikoffDTDhaval TrivediRKRichard Kwock

Key Points

Key points are not available for this paper at this time.

Abstract

Kaiser-Permanente Los Angeles Medical Center (LAMC) is a 560 licensed bed facility that provides regional cardiovascular services, including 1200 open heart surgeries annually. In 2021, LAMC explored alternative therapies to offset the impact of pandemic-driven cryo AHF shortages, and implemented Pathogen Reduced Cryoprecipitated Fibrinogen Complex (also known as INTERCEPT Fibrinogen Complex or IFC). IFC is approved to treat and control bleeding associated with fibrinogen deficiency. Unlike cryo AHF, IFC has 5-day post-thaw shelf life with potential operational and clinical benefits. The implementation steps and the operational advantages to the LAMC Blood Bank are described.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Aidikoff et al. (2024) studied this question.

synapsesocial.com/papers/68e60f5cb6db6435875a1ff4https://doi.org/10.1111/trf.17940
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Implementation and early outcomes with Pathogen Reduced Cryoprecipitated Fibrinogen Complex2024 · 5 citations
  2. 2Retention of critical platelet hemostatic functions of amotosalen‐ <scp>UVA</scp> pathogen‐reduced cryoprecipitated fibrinogen complex2026
  3. 3Implementation of pathogen reduced cryoprecipitate for surgical services: A retrospective review of blood product utilization and fibrinogen repletion2025
  4. 4Fibrinogen concentrates versus cryoprecipitate for intraoperative hypofibrinogenemia in liver transplantation: study protocol for a randomized trial (FIBCRYO-LT trial)2026
  5. 5The Second Battle: Equipping Austere Surgical Teams for Post-Resuscitation Coagulopathy2026